NPL.SI volume 170,000 on 14 Feb 2026: Niks Professional S$0.23 pre-market signal

A sharp volume spike of 170,000 shares puts the NPL.SI stock into focus in the Singapore pre-market on 14 Feb 2026. The stock trades at S$0.23 with average volume near 3,200, giving a relative volume of 53.13. This abnormal activity signals higher liquidity and potential re-rating interest in Niks Professional Ltd on the SES. We track drivers behind the move, compare fundamentals to sector peers, and flag key technical levels that traders watch today.

NPL.SI stock pre-market volume spike and trade facts

The immediate fact is the 170,000 share print against an avgVolume 3,200, a relVolume 53.13 reading. Price sits at S$0.23 (open S$0.23, previous close S$0.23). One claim per point: the spike is liquidity driven and not a steady trend. Volume concentration can attract short-term traders. Watch order book depth when SES opens for confirmation of follow-through.

Fundamentals and valuation for Niks Professional Ltd (NPL.SI stock)

Niks Professional Ltd reports EPS S$0.01 and a reported PE 23.00 per latest quotes. Trailing metrics show book value per share S$0.15 and cash per share S$0.06. Profitability ratios include net margin 17.21% and return on equity 9.76%. One claim: on a price-to-book of 1.53, the stock sits near fair book valuation versus small-cap healthcare peers. The company operates clinics and retail skincare in Singapore and posts low leverage with debt to equity 0.06.

Technical snapshot and volume-driven trade set-up for NPL.SI stock

Momentum indicators show neutral RSI 47.15 and ADX 16.63, indicating no established trend. Bollinger middle band is S$0.23, and price currently sits at that band. One claim: the key technical trigger is the large volume spike paired with OBV of 209,000, which suggests buyers entered in size. Short-term targets: watch resistance S$0.28 and support S$0.20. Tight stops suit this small-cap name due to high intraday volatility.

Meyka AI rates NPL.SI with a score out of 100 and model forecast

Meyka AI rates NPL.SI with a score of 67.01 out of 100: Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. This grade is not guaranteed and we are not financial advisors. Meyka AI’s forecast model projects monthly S$0.23, quarterly S$0.25, and yearly S$0.3256. Compared with the current price S$0.23, the 12-month implied upside is 41.55%. Forecasts are model-based projections and not guarantees.

Catalysts, sector context, and risks for NPL.SI stock

Catalysts include clinic expansion, higher retail product sales, and Singapore healthcare demand. One claim: sector trends show healthcare on SES with modest YTD weakness, making Niks a niche outpatient play. Key risks include concentration in Singapore, small free float, and earnings volatility. Watch dividend signal: the company reports dividend per share S$0.24 historically, but dividend growth is uneven. Liquidity spikes can amplify downside quickly on negative news.

Trading strategy and price targets for the pre-market volume spike

For volume-spike traders, one claim per rule: trade small position sizes and use tight stops. Short-term price target S$0.28 and medium-term target S$0.33 (12 months). A conservative downside scenario is S$0.17 if volume reverses. Use limit orders to manage execution cost on SES. Track daily average volume and order-book prints to confirm whether early spike leads to sustained accumulation.

Final Thoughts

The NPL.SI stock shows an outsized pre-market volume print of 170,000 shares on 14 Feb 2026 while trading at S$0.23. That relative volume of 53.13 is the most actionable signal today and requires confirmation at open. Fundamentals show reasonable margins, low leverage, and a mixed valuation profile with PE 23.00 and PB 1.53. Meyka AI’s models project a 12-month price near S$0.33, implying ~41.55% upside from the current price; forecasts are model-based and not guarantees. For traders, the immediate plan is to watch order-book follow-through, set a short-term target around S$0.28, and keep size small because small caps can reverse quickly. For longer-term investors, the Meyka grade B HOLD reflects solid balance-sheet ratios but limited liquidity and operational scale. We note two primary watch points: whether volume persists after open, and any company updates on clinic growth or retail sales. For live order-book checks and further updates, see the company site and SGX announcements and our Meyka AI-powered market analysis.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.